TransUnion 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TransUnion on October 26, 2021. The filing discloses the entry into a Material Definitive Agreement regarding the divestiture of a specific business segment.
Key Financial Metrics and Transaction Details
- Transaction Type: Sale of the healthcare revenue cycle management and data analytics insights business.
- Purchase Price: Aggregate of $1.735 billion, subject to customary adjustments for working capital, cash, indebtedness, and transaction expenses.
- Purchaser: nThrive, Inc., a Delaware corporation backed by Clearlake Capital Group L.P. and affiliated funds.
- Financing: The Purchaser has secured equity commitments from Sponsor-affiliated funds and a debt financing commitment led by JPMorgan Chase Bank, N.A.
- Termination Fee: A Reverse Termination Fee of $112.775 million is payable by the Purchaser under specific termination circumstances, guaranteed by certain Sponsor-affiliated funds.
Material Changes and Outlook
The filing does not report changes to TransUnion's consolidated revenue, profit, or cash flow for a specific reporting period, as this is a current report regarding a pending transaction. The Company targets closing the transaction in the fourth quarter of 2021, subject to customary closing conditions including the expiration of the Hart-Scott-Rodino waiting period and the absence of governmental injunctions.
Risks, Contingencies, and Management Commentary
- Closing Conditions: The transaction is contingent on regulatory approvals and the absence of laws prohibiting the consummation.
- Termination Rights: Either party may terminate the agreement under specific circumstances, including mutual consent, permanent governmental injunction, failure to close by the "Outside Date" of April 26, 2022, or uncured material breaches.
- Operational Continuity: Between signing and closing, TransUnion agrees to conduct the business in the ordinary course and maintain its goodwill.
- Legal Disclaimer: Representations and warranties in the agreement are not categorical statements of fact and do not survive post-closing.
Investor Verification Checklist
- Verify the final closing date and whether the transaction closes in Q4 2021 as targeted.
- Monitor regulatory filings for the expiration of the Hart-Scott-Rodino waiting period.
- Review the final purchase price adjustments related to working capital, cash, and indebtedness at closing.
- Confirm the status of the debt financing commitment led by JPMorgan Chase Bank, N.A.
- Check for any subsequent filings regarding the termination of the agreement or the Outside Date of April 26, 2022.